Last updated: August 27, 2026
Dynavax Technologies is a focused vaccine company whose commercial position depends primarily on HEPLISAV-B, the only two-dose adult hepatitis B vaccine marketed in the United States. Its competitive advantage is the CpG 1018 adjuvant, which improves seroprotection rates and shortens the dosing schedule relative to three-dose products. The principal risks are concentration in one commercial product, hospital and public-sector contracting, manufacturing scale, competing hepatitis B vaccines, and long-dated but potentially challengeable patent protection.
Dynavax Technologies Competitive Landscape: Market Position, Patent Estate, HEPLISAV-B and Strategic Risks
What is Dynavax Technologies’ market position?
Dynavax Technologies Corporation is a commercial-stage vaccine biotechnology company headquartered in Emeryville, California. Its lead product is HEPLISAV-B, a recombinant hepatitis B vaccine for adults aged 18 years and older.
HEPLISAV-B combines recombinant hepatitis B surface antigen with CpG 1018, a toll-like receptor 9 agonist adjuvant. The product uses a two-dose schedule administered one month apart. Competing adult hepatitis B vaccines generally require three doses over six months, although schedules vary by product and patient population.
HEPLISAV-B was approved by the U.S. Food and Drug Administration on Nov. 9, 2017. The product is marketed in the United States by Dynavax and is manufactured through external and internal supply-chain arrangements disclosed in company filings (U.S. Food and Drug Administration, 2017; Dynavax Technologies Corporation, 2024a).
| Factor |
Dynavax position |
| Lead commercial product |
HEPLISAV-B |
| Active antigen |
Recombinant hepatitis B surface antigen |
| Adjuvant |
CpG 1018 |
| U.S. indication |
Prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years and older |
| Dosing schedule |
Two doses at 0 and 1 month |
| FDA approval |
Nov. 9, 2017 |
| Primary market |
U.S. adult hepatitis B vaccination |
| Main competitors |
Engerix-B, Recombivax HB, PreHevbrio, supply from public-health programs |
| Strategic platform |
CpG 1018 adjuvant licensing and collaboration |
Dynavax has a narrower commercial portfolio than diversified vaccine companies such as GSK, Sanofi and Merck. That concentration creates operating leverage if HEPLISAV-B continues gaining share, but it also creates product, regulatory and manufacturing exposure.
How does HEPLISAV-B compare with competing hepatitis B vaccines?
HEPLISAV-B’s principal commercial advantage is schedule completion. A two-dose regimen may reduce missed appointments and improve protection in adults who face barriers to completing a longer vaccination series.
The vaccine also showed higher seroprotection rates than Engerix-B in pivotal studies. In the FDA-approved prescribing information, HEPLISAV-B produced seroprotection rates of approximately 90% and 95% in two pivotal adult studies, compared with approximately 81% and 81% for Engerix-B in the corresponding trials (Dynavax Technologies Corporation, 2024b).
| Product |
Manufacturer |
Adult schedule |
Key competitive issue |
| HEPLISAV-B |
Dynavax |
2 doses over 1 month |
Higher seroprotection and faster completion |
| Engerix-B |
GSK |
Generally 3 doses over 6 months |
Established institutional presence |
| Recombivax HB |
Merck |
Generally 3 doses over 6 months |
Established brand and distribution |
| PreHevbrio |
VBI Vaccines |
3 doses |
U.S. commercial availability materially weakened after manufacturing and corporate problems |
The commercial comparison is not limited to immunogenicity. Hospital formularies, government procurement, payer reimbursement, inventory contracts and vaccination workflow affect product selection. Established competitors retain advantages in contracting, distribution and physician familiarity.
What is the commercial value of the two-dose schedule?
The two-dose schedule gives HEPLISAV-B a meaningful position in occupational health, pharmacies, dialysis centers, correctional facilities and other settings where rapid vaccination completion matters. It is also relevant for adults with diabetes and other groups with historically lower vaccination adherence.
The U.S. Centers for Disease Control and Prevention recommends hepatitis B vaccination for all adults aged 19 through 59 years and for adults aged 60 years and older with risk factors or without an identified risk factor who seek protection (Centers for Disease Control and Prevention, 2024).
The addressable market is large, but annual revenue depends on adult vaccination uptake rather than on chronic treatment. This makes demand more sensitive to employer programs, pharmacy execution, public-health budgets and seasonal purchasing.
What patents protect HEPLISAV-B?
HEPLISAV-B is protected by a portfolio covering CpG 1018, vaccine compositions, adjuvant-antigen combinations, dosing regimens and manufacturing or formulation technology. The company has disclosed that issued patents covering the product extend into the late 2020s and, for certain rights, into the 2030s, subject to patent scope, terminal disclaimers, validity challenges and regulatory exclusivity (Dynavax Technologies Corporation, 2024a).
Because HEPLISAV-B is a licensed biologic, it is not governed by the same Orange Book listing framework used for small-molecule drugs. Relevant biologic reference-product and patent information is evaluated through the Public Health Service Act and FDA Purple Book framework rather than through a conventional Orange Book patent listing.
| Protection category |
Strategic role |
Expected risk profile |
| CpG 1018 composition and use |
Protects the adjuvant platform and immunostimulatory application |
Potential invalidity and written-description challenges |
| Vaccine composition |
Protects combinations of hepatitis B antigen and CpG 1018 |
Important barrier to biosimilar or follow-on products |
| Dosing regimen |
Protects two-dose adult vaccination methods |
Vulnerable to design-around and claim-construction disputes |
| Formulation and manufacturing |
Protects stability, concentration and production methods |
May create practical barriers even after core composition expiry |
| Regulatory exclusivity |
Delays certain follow-on biologic approvals |
Separate from patent term |
Patent protection must be assessed claim by claim. A patent covering CpG 1018 alone may not block a competitor using a different adjuvant. A claim limited to a hepatitis B antigen and specified oligonucleotide sequence may also be avoided through a materially different formulation or immunostimulatory mechanism.
When does HEPLISAV-B lose exclusivity?
HEPLISAV-B does not have a single exclusivity-loss date. The relevant dates include FDA biologic reference-product exclusivity, individual patent expirations, pediatric exclusivity, regulatory approval timing and the commercial feasibility of a competing product.
The 12-year U.S. reference-product exclusivity period for a licensed biologic is generally measured from the date of first licensure. On that framework, HEPLISAV-B’s reference-product exclusivity period would extend to approximately November 2029, absent a different statutory treatment or regulatory determination. A biosimilar application could be submitted earlier, but FDA approval would be restricted until the applicable exclusivity period ends under the Biologics Price Competition and Innovation Act.
| Milestone |
Date or period |
| FDA approval |
Nov. 9, 2017 |
| Approximate 12-year reference-product exclusivity endpoint |
Nov. 2029 |
| Publicly disclosed patent coverage |
Late 2020s through certain rights in the 2030s |
| Practical generic entry |
More likely through a biosimilar or follow-on biologic pathway than an ANDA |
A competitor could attempt a 351(k) biosimilar pathway, a 351(a) full biologics license application, or a different vaccine product based on a non-infringing adjuvant. The commercial effect of each pathway would differ. A 351(k) product would face biosimilarity and interchangeability requirements. A new vaccine with a distinct adjuvant could avoid HEPLISAV-B patents but would require independent clinical and regulatory development.
What is the Orange Book and Purple Book status of HEPLISAV-B?
HEPLISAV-B is not an Orange Book-listed small-molecule drug. Its regulatory status is that of a licensed biologic under a Biologics License Application, or BLA.
The FDA Purple Book identifies licensed biological products and relevant reference-product information. Patent disputes involving biologics are not managed through the same statutory patent-certification process used for an ANDA applicant challenging an Orange Book-listed drug.
Does HEPLISAV-B face Paragraph IV challenges?
No conventional Paragraph IV challenge is expected to operate against HEPLISAV-B because Paragraph IV certifications apply to ANDA applicants challenging Orange Book-listed patents. A competing biologic would instead face the BPCIA framework, including patent information exchange procedures, potential patent litigation and the statutory requirements for biosimilar approval.
This distinction reduces the usefulness of traditional generic-entry analysis. The key questions are whether a competitor can establish biosimilarity, whether it can avoid or invalidate Dynavax patents, whether it will pursue interchangeability, and whether the commercial opportunity justifies the cost of vaccine development.
What formulation and method-of-use patents protect Dynavax?
Dynavax’s formulation and method-of-use position is strategically important because CpG 1018 is a platform adjuvant rather than a product-specific chemical entity.
Potential protection areas include:
- Combination of CpG 1018 with hepatitis B surface antigen.
- Use of CpG 1018 to accelerate adult hepatitis B vaccination.
- Specified dose levels and administration intervals.
- Formulation stability and storage characteristics.
- Manufacturing controls for oligonucleotide adjuvant production.
- Use in populations with reduced vaccine response.
- Combination with antigens for non-hepatitis B vaccines.
Formulation patents can remain commercially relevant after core composition claims expire if they cover the product’s marketed concentration, stability profile or manufacturing process. Their value depends on whether a competitor can use a different concentration, excipient system, sequence, production method or delivery format.
Which companies are competing with or challenging Dynavax?
The competitive field has three layers.
Direct hepatitis B vaccine competitors
GSK and Merck are the principal established branded competitors through Engerix-B and Recombivax HB. Their advantages include global infrastructure, broad vaccine portfolios and institutional contracting relationships.
VBI Vaccines’ PreHevbrio received FDA approval in 2021, but its commercial position deteriorated after manufacturing-related issues and corporate financial distress. The product’s reduced availability lowered near-term competitive pressure but did not eliminate the possibility of future alternative hepatitis B vaccines.
Platform-adjuvant competitors
Dynavax competes indirectly with companies that control alternative adjuvant systems, including GSK’s AS04, Novavax’s Matrix-M and proprietary adjuvants used by large vaccine manufacturers. Alternative adjuvants can support vaccines that avoid CpG 1018 patent claims.
Biosimilar and follow-on developers
No major biosimilar competitor has publicly established a commercial HEPLISAV-B launch timetable in the public information reviewed through 2024. The more credible medium-term threat is a follow-on hepatitis B vaccine with a different adjuvant or a 351(k) product developed after the reference-product exclusivity period.
What licensing deals support Dynavax’s strategic position?
Dynavax has used CpG 1018 licensing and supply agreements to extend the platform beyond HEPLISAV-B. During the COVID-19 vaccine program, the company entered collaborations involving Clover Biopharmaceuticals, Valneva, Medigen Vaccine Biologics and other developers.
The commercial value of those arrangements varies. Some agreements generated near-term adjuvant sales, while others depended on vaccine approvals, procurement and clinical success. COVID-19-related revenue was not a substitute for durable HEPLISAV-B growth because pandemic vaccine demand declined sharply after the emergency phase.
| Partner or program |
Relationship to CpG 1018 |
Strategic relevance |
| Clover Biopharmaceuticals |
Adjuvant collaboration for COVID-19 vaccine development |
Demonstrated platform utility |
| Valneva |
CpG 1018 collaboration for COVID-19 vaccine program |
Expanded international platform exposure |
| Medigen |
CpG 1018 collaboration |
Supported regional vaccine development |
| Other vaccine developers |
Supply, licensing or evaluation arrangements |
Potential royalty and product-supply revenue |
The key licensing question is whether Dynavax can convert CpG 1018 into recurring royalty, milestone or supply revenue from approved vaccines. Most platform collaborations do not create material value until a partner obtains regulatory approval and achieves commercial scale.
How strong is Dynavax’s patent estate?
Dynavax’s patent estate is strongest where three conditions overlap: CpG 1018 is required, the marketed formulation falls within the claims, and the product is used in a commercially valuable vaccine.
Strengths
- HEPLISAV-B has a differentiated two-dose regimen.
- CpG 1018 creates composition and platform claims beyond the hepatitis B antigen.
- The product has FDA approval and clinical data supporting the selected regimen.
- Certain patents extend beyond the earliest expected biologic exclusivity endpoint.
- Manufacturing know-how may be difficult to replicate even where patent claims are narrow.
Weaknesses
- The estate is concentrated around one commercial product.
- Adjuvant patents can be designed around through alternative sequences or mechanisms.
- Method-of-use claims may face eligibility, written-description or obviousness challenges.
- Biosimilar developers can select a non-identical process or formulation.
- The commercial value of platform patents depends on partner adoption and regulatory approvals.
Overall, the estate is commercially meaningful but not immune to design-around risk. Its value is higher for a direct HEPLISAV-B copy than for a competing hepatitis B vaccine using a different adjuvant.
What patent litigation and settlement agreements affect HEPLISAV-B?
No major public Paragraph IV litigation framework applies because HEPLISAV-B is a biologic rather than an Orange Book-listed small molecule. Publicly disclosed litigation risk therefore centers on BPCIA patent disputes, patent validity actions, license disagreements and contract litigation involving manufacturing or supply.
No widely reported settlement agreement has established an authorized biosimilar launch date for HEPLISAV-B through 2024. The absence of a public settlement reduces near-term visibility into an agreed generic or biosimilar entry date.
What is Dynavax’s revenue exposure?
Dynavax’s financial exposure is concentrated in HEPLISAV-B product sales. CpG 1018 collaborations provide diversification, but platform revenue has been affected by the decline in COVID-19 vaccine demand.
HEPLISAV-B growth depends on:
- Share gains from three-dose hepatitis B vaccines.
- Pharmacy and retail vaccination expansion.
- Employer and occupational-health programs.
- Adult vaccination recommendations.
- Medicare, commercial insurance and public-sector reimbursement.
- Manufacturing capacity and product availability.
The principal financial risk is a mismatch between clinical differentiation and market access. A better schedule does not automatically produce rapid share conversion where institutions have long-standing contracts with GSK or Merck.
What generic or biosimilar launch risks exist?
The most plausible launch scenarios are:
| Scenario |
Timing |
Commercial effect |
| No direct follow-on product |
Before 2029 |
Dynavax retains high protection if sales expand |
| Alternative-adjuvant hepatitis B vaccine |
Before or after 2029 |
Moderate threat; requires new clinical and regulatory investment |
| 351(k) biosimilar |
Around or after 2029 |
High threat if interchangeability and contracting are achieved |
| Patent challenge with settlement |
Before patent expiry |
Entry date depends on negotiated terms |
| Manufacturing-driven disruption |
Any time |
Could weaken Dynavax’s share without patent expiry |
A true “generic launch” is less likely than a biologic follow-on launch. Substitution would also depend on FDA interchangeability, payer policy and provider procurement, not only FDA approval.
How does Dynavax compare with larger vaccine manufacturers?
| Dimension |
Dynavax |
GSK and Merck |
| Commercial focus |
Concentrated vaccine portfolio |
Broad vaccine franchises |
| Hepatitis B differentiation |
Two-dose HEPLISAV-B regimen |
Established three-dose products |
| Distribution |
Smaller commercial infrastructure |
Global sales and contracting networks |
| Patent leverage |
CpG 1018 and HEPLISAV-B estate |
Product-specific and platform portfolios |
| Financial diversification |
Limited |
High |
| Manufacturing resilience |
More concentrated |
Larger network and redundancy |
| Strategic upside |
HEPLISAV-B share gains and CpG licensing |
Portfolio-wide vaccine growth |
Dynavax has a product-level innovation advantage, while larger competitors have scale, procurement access and manufacturing redundancy. The company’s strategic value rises if it can establish CpG 1018 as a repeat-use adjuvant platform rather than a single-product technology.
What geographic coverage does Dynavax have?
HEPLISAV-B’s principal commercial market is the United States. Dynavax has pursued international opportunities for CpG 1018 through licensing and development collaborations, but the global commercial footprint is less extensive than that of GSK, Sanofi or Merck.
Geographic expansion faces several barriers:
- Country-specific vaccine registration requirements.
- Local manufacturing or fill-finish expectations.
- Government tender pricing.
- National immunization schedules.
- Data requirements for foreign populations.
- Partner dependence for distribution and commercialization.
The U.S. market remains the central value driver. International CpG 1018 licensing is strategically useful but does not carry the same near-term revenue visibility as HEPLISAV-B.
What should investors and business-development teams monitor?
The highest-value indicators are:
- HEPLISAV-B prescription, institutional and pharmacy share.
- Net product revenue growth and gross-margin performance.
- Manufacturing capacity and supply continuity.
- New CpG 1018 licensing agreements that include commercial supply or royalties.
- FDA or partner approvals for CpG 1018-containing vaccines.
- Purple Book activity and any 351(k) development.
- Patent prosecution, maintenance and litigation involving CpG 1018.
- Public-sector contracting and adult vaccination policy.
- Competitive pricing from Engerix-B and Recombivax HB.
- Any settlement that establishes an early follow-on entry date.
Key Takeaways
- HEPLISAV-B is Dynavax’s core commercial asset and the company’s primary revenue driver.
- Its two-dose schedule and high seroprotection rates distinguish it from traditional three-dose hepatitis B vaccines.
- GSK and Merck remain the strongest direct competitors because of scale, contracting and distribution.
- HEPLISAV-B is a biologic, so Orange Book and Paragraph IV analysis do not directly apply.
- Approximate U.S. reference-product exclusivity runs to November 2029 under the 12-year biologic framework.
- Dynavax has disclosed patent coverage extending from the late 2020s into the 2030s for certain rights.
- The patent estate is strongest against direct CpG 1018-based copies and weaker against vaccines using different adjuvants.
- CpG 1018 licensing provides strategic upside, but COVID-19-related demand is no longer a dependable growth engine.
- The main commercial risk is product concentration combined with the procurement power of larger vaccine manufacturers.
- The most credible long-term entry threat is a follow-on biologic or alternative-adjuvant hepatitis B vaccine, not a conventional generic.
FAQs
Can HEPLISAV-B be substituted automatically for Engerix-B or Recombivax HB?
Automatic substitution depends on applicable FDA labeling, interchangeability status, state law and payer or institutional policy. HEPLISAV-B’s two-dose schedule makes it clinically differentiated, but schedule differences can limit direct substitution mechanics.
Does CpG 1018 have value outside hepatitis B vaccines?
Yes. CpG 1018 can function as an adjuvant for multiple antigen types. Its commercial value depends on partner clinical data, regulatory approval, manufacturing scale and the economics of royalties or adjuvant supply.
Could a competitor avoid Dynavax patents by using a different TLR agonist?
Potentially. A vaccine using a different adjuvant may avoid claims limited to CpG 1018 or specified oligonucleotide sequences, although it would require separate clinical development and regulatory approval.
Is HEPLISAV-B exposed to biosimilar interchangeability risk?
Yes, over the longer term. A biosimilar or interchangeable product could create substantial price and market-share pressure, but it would need to satisfy FDA requirements and overcome Dynavax’s applicable patent and regulatory protections.
What is the most important diligence issue for a Dynavax license?
The critical issue is whether the agreement produces recurring commercial economics. A license with only development rights has limited near-term value unless it includes milestones, royalties, minimum purchases or a binding commercial supply commitment.
References
Centers for Disease Control and Prevention. (2024). Hepatitis B vaccine administration. https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/
Dynavax Technologies Corporation. (2024a). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/
Dynavax Technologies Corporation. (2024b). HEPLISAV-B prescribing information. https://www.heplisavb.com/
U.S. Food and Drug Administration. (2017). FDA approves vaccine to prevent hepatitis B in adults. https://www.fda.gov/news-events/press-announcements/fda-approves-vaccine-prevent-hepatitis-b-adults
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
